1. Home
  2. JG vs RNTX Comparison

JG vs RNTX Comparison

Compare JG & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Mobile Limited

JG

Aurora Mobile Limited

HOLD

Current Price

$7.66

Market Cap

40.6M

Sector

Technology

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.55

Market Cap

35.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JG
RNTX
Founded
2012
2001
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.6M
35.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
JG
RNTX
Price
$7.66
$1.55
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
7.6K
195.3K
Earning Date
03-12-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,967,244.00
N/A
Revenue This Year
$10.90
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
20.78
N/A
52 Week Low
$5.85
$1.02
52 Week High
$20.94
$3.50

Technical Indicators

Market Signals
Indicator
JG
RNTX
Relative Strength Index (RSI) 56.74 66.46
Support Level $6.71 $1.12
Resistance Level $8.10 $1.25
Average True Range (ATR) 0.56 0.11
MACD 0.06 0.05
Stochastic Oscillator 58.89 84.91

Price Performance

Historical Comparison
JG
RNTX

About JG Aurora Mobile Limited

Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates and generates its revenue from the People's Republic of China.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: